#China #Suzhou #Innovent Biologics #Thyroid Eye Disease #SYCUME®

Innovent's Breakthrough in Thyroid Eye Disease Management

Innovent Biologics, Inc. has made significant strides in the treatment of inactive Thyroid Eye Disease (TED) with their recent announcement regarding SYCUME® (Teprotumumab N01 Injection). This innovative treatment has successfully met its primary endpoint in the Phase 3 RESTORE-3 clinical trial, showcasing promising efficacy and a favorable safety profile for patients with inactive TED.

What is Thyroid Eye Disease?

Thyroid Eye Disease is an autoimmune condition that primarily affects the ocular tissues. It is often associated with Graves' disease but can occur in those with other thyroid disorders or even in individuals with normal thyroid function. Approximately 25% to 40% of those with Graves' disease may experience TED, which can significantly impact quality of life due to eye-related symptoms such as proptosis, diplopia, and discomfort.

The RESTORE-3 Trial

The RESTORE-3 trial was a multicenter, randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of SYCUME® in Chinese participants with inactive TED. A total of 116 participants were involved in this study, with a mean disease duration of 4.3 years. The trial aimed to assess how effectively SYCUME® could reduce proptosis—the bulging of the eye—which is a common symptom of TED.

Key Findings

The results from Week 24 of the trial were particularly remarkable:

• - The proptosis response rate in participants receiving SYCUME® was 60.4% compared to only 23.5% in the placebo group.
• - The average reduction in proptosis distance was -1.88 mm in the SYCUME® group, which significantly outperformed the placebo group's reduction of -0.88 mm.
• - Encouragingly, the non-study eyes also demonstrated improved outcomes, suggesting broader systemic benefits beyond just the targeted eye.

Safety Profile

During the study, SYCUME® exhibited a good safety profile, with most treatment-emergent adverse events being mild to moderate. No new safety signals were identified, reinforcing confidence in the drug’s use.

A Novel Treatment Paradigm

Professor Zhongyan Shan, the Lead Principal Investigator of the study, emphasized that until now, effective pharmacological options for managing inactive TED have been scarce, often leading patients to endure significant proptosis and facial disfigurement without sufficient medical intervention. SYCUME® provides hope for these patients, offering a non-surgical treatment approach to an otherwise chronic condition. This advancement not only serves patients but also enhances clinical strategies for managing the disease.

Accessibility and Future Outlook

SYCUME® is notable for being the first IGF-1R antibody approved in China, fulfilling a crucial gap in treatment options that has persisted for over 70 years. After its inclusion in the National Reimbursement Drug List in January 2026, the financial burden on patients has been substantially reduced, allowing broader access to this pioneering treatment.

Dr. Lei Qian from Innovent articulated the company's commitment to improving patient outcomes in TED, highlighting that SYCUME® is integral in addressing the full spectrum of the disease—from acute control to chronic management.

As the follow-up to the RESTORE-3 trial progresses, further analyses will continue to shape clinical practices, potentially revolutionizing how TED is managed moving forward. Innovent's ongoing research and dedication to patient welfare reflect a promising era in biopharmaceutical innovation aimed at improving life quality for those suffering from TED.

Conclusion

The results of the RESTORE-3 study propel SYCUME® to the forefront of TED treatment, presenting vital new options for patients and marking a significant evolution in ocular disease management. Innovent Biologics stands testament to how targeted therapies can redefine care standards in chronic health conditions.